We have observed that NPC-1S669, a leucine derivative with anti-inflammatory activity, reduced the proliferation of human aortic smooth muscle cells (HASMCs) in culture. We used a colorimetric assay and tritiated thymidine to measure the cell density and proliferation of HASMC cultures treated with this agent. We also studied the effect of NPC-15669 on the proliferation and migration of human aortic endothelial cells (HAECs). Subconfluent HASMC cultures were growth arrested for 2 days. On the third day, growth was stimulated with either growth media (medium Ml99 containing 10% fetal bovine serum [FBS]), human platelet-derived growth factor (hPDGF), or fibroblast growth factor (FGF) in the absence or presence of NPC-15669 (0.1-50 fiM). Regardless of the stimulating agent for HASMCs (FBS, hPDGF, or FGF), NPC-15669 at concentrations of 10-25 /xM caused a significant reduction in thymidine incorporation (36.7% and 77.2% in 10 pM and 25 fiM, respectively; p<0.005) and cell density (25-87%, p<0.001) compared with control. NPC-15669 did not, however, have an effect on the rate of proliferation or migration of HAECs, even at concentrations up to 50 fiM. Two other anti-inflammatory agents, aspirin and dexamethasone, caused substantially and significantly less inhibition, even at high concentrations (50 and 25 /iM, respectively). This study demonstrates that in vitro, NPC-15669 significantly inhibits HASMC proliferation but has no effect on proliferation or migration of HAECs. (PTCA) is widely used as the initial procedure of choice for the nonpharmacologic treatment of coronary artery disease. Advances in technique and equipment have improved the early patency rate; however, restenosis due to intimal hyperplasia continues to be a major problem. Intimal hyperplasia results from migration of smooth muscle cells (SMCs) from the media to the intima, where they proliferate and produce large amounts of matrix.
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2 This response is thought to be a reparative response to the vascular injury caused by angioplasty. 3 The control of this response, though poorly understood, appears to play a significant role in the development of restenosis. Previous attempts to control restenosis have failed. Figure 1 ), on proliferating human aortic endothelial cells (HAECs) and human aortic smooth muscle cells (HASMCs) in vitro. We observed that in HASMCs stimulated to proliferate in vitro with either human platelet-derived growth factor (hPDGF), fetal bovine serum (FBS), or fibroblast growth factor (FGF), NPC-15669 significantly reduced or abolished proliferation without affecting the proliferation or migration of HAECs. Two other anti-inflammatory agents, aspirin and dexamethasone, at concentrations up to 50 and 25 M, respectively, produced significantly less inhibition (35% and 25%, respectively) on HASMC proliferation. These results suggest that NPC-15669 warrants further investigation as a possible agent for the prevention of post-PTCA restenosis.
(

Methods
Materials
Trypsin and phosphate-buffered saline (PBS) were purchased from GIBCO, Grand 
Colorimetric Assay
Cell density used to assess proliferation was determined indirectly by a modified crystal violet colorimetric assay described by Gillies et al. 5 HASMC and HAEC proliferation in 96-well gelatinized tissue culture plates was assayed by the following method. The plates were washed with PBS and then fixed with 50 ntL/well of a 10% (vol/vol) solution of neutral buffered formalin for 30 minutes. Staining was achieved by a 30-minute incubation with 100 /ilVwell of a 0.1% (wt/vol) crystal violet solution in distilled water. The plates were washed five times with distilled water; the intracellular dye was then eluted with 200 /xL/well of a 0.2% (vol/vol) Triton X-100 solution. The plates were protected from evaporation and stored overnight at room temperature. The optical density at 590 nm was then determined using an optical reader for 96-well plates (Molecular Devices, Menlo Park, Calif.). The results of this colorimetric assay correlated closely with those of direct cell counting that were obtained by using an electronic particle counter (Coulter Electronics, Hialeah, Fla.) for both HAECs and HASMCs (/-=0.99, Figure 2) . By using the resulting linear regression equation, the optical density readings from subsequent plates were converted to cell density in cells per square centimeter.
Isolation and Culture of HASMCs
Cells were obtained from human aortic tissue excised from normal donor hearts at the time of cardiac transplantation at the UCLA Medical Center. Culture methods were previously described. 6 Briefly, the tissue was placed in 0.2% type I collagenase (Worthington Biochemical, Freehold, N.J.) in M199 medium-PBS (1:1, vol/vol) for 30 minutes at 37°C to enzymatically remove the ECs. These cells were propagated and stored at -196°C for later use. The medial layer was isolated rapidly in ice-cold PBS and cut into lxl-mm explants. The explants were then placed in gelatinized tissue culture dishes and allowed to adhere for 15-30 minutes. A sterile coverslip was placed over the minced tissue to promote attachment and prevent flotation. M199 medium supplemented with 20% FBS was added gently to the wells. After 5-7 days, the SMCs had grown out onto the tissue culture wells. The aortic tissue was then removed, and the cells were allowed to grow for 2-3 days, then isolated by digestion with 0.01% trypsin in 2 mM EDTA, washed, and propagated for up to 6 passages. The cells were stored at -196°C in M199 medium containing 20% FBS and 10% dimethyl sulfoxide. The cryopreserved cells used for this study were at passage levels 4-6. Each experiment was repeated with cells from at least three different donors.
Effect of NPC-15669, Aspirin, and Dexamethasone on FBS-Stimulated HASMCs
Cells obtained from liquid nitrogen storage were quickly thawed in a 37°C water bath and immediately washed with 10 volumes of growth medium. Gelatinized 96-well tissue culture plates were seeded with 150 ju-L/well of cell suspension (10,000 cells/well). The cells were incubated in their initial growth medium in humidified 95% air and 5% CO 2 at 37°C for 3 days; by the third day, the cultures were 70-90% confluent. The cells were then growth arrested in medium M199 con- taining 2% plasma-derived human serum (PDS) for 2 days. On the third day, cell density was measured for plate No. 1 from each donor to determine the baseline for each condition. Media in the remaining plates were changed to fresh growth media (control), one of four different NPC-15669 concentrations (1, 5, 10, or 25 /xM), one of three different aspirin concentrations (1, 25, or 50 /u.M), or one of three different dexamethasone concentrations (1, 10, or 25 ptM) in the growth media. Each plate contained 16 wells of each concentration, 16 control wells, and 16 wells containing growth medium but no cells to serve as blanks for the colorimetric assay. The total amount of NPC-15669, aspirin, or dexamethasone in each well was replenished daily by adding 20 (JLL of an 8.5 x concentration of the appropriate agent in PBS. Control wells and blank wells received 20 /xL PBS. Cell density for each condition was measured on days 0 (baseline), 3, 6, and 9. Every third day, each well of the remaining plates had half (75 fiL) of its medium replaced with fresh growth medium containing a 2x concentration of the appropriate agent. The control wells and blank wells received 75 fiL of fresh growth medium in parallel.
FIGURE 2. Regression line showing validation of the crystal violet colorimetric assay for cell density by comparison with automatic cell counting (Coulter
There is some suggestion that NPC-15669 is stable at physiological temperature and pH for no more than 24 hours. Consequently, we made new additions daily to maintain constant, biologically active concentrations. To avoid alterations incurred as a result of frequent media changes, we changed half of the medium every third day. If one assumes that NPC-15669 was stable and biologically active, then the concentrations of NPC-15669 and the other compounds tested would have been twice, three times, and five times those shown in the figures at days 3, 6, and 9, respectively.
Recovery of NPC-15669-Treated HASMCs
HASMCs, passages 4-6, were grown and growth arrested as described above. The cells were then stimulated with 10% FBS (growth medium) containing either 0, 10, or 25 nM NPC-15669 for a total of 9 days. On the ninth day, cell density was determined for each concentration. The remaining plates had all concentrations of NPC-15669-containing media changed to fresh growth media without NPC-15669; this is considered day 0 of recovery. Cell density determinations were made on days 3 and 6 after NPC-15669 removal.
Effect of NPC-15669 on hPDGF-and FGF-Stimulated Cells
NPC-15669 was also tested in hPDGF-and FGFstimulated cells. The cells were grown and growth arrested as described above. On the third day after growth arrest, cells were stimulated by adding 0, 1, 10, or 25 fiM NPC-15669 to either medium M199+5 ng/mL h P D G F + 1 % PDS or medium M199+100 /xM FGF+1% PDS. Cell density for each condition was measured on days 0 (baseline), 2, and 4.
Effect of NPC-15669 on Thymidine Incorporation in hPDGF-Stimulated HASMCs
One gelatinized 96-well tissue culture plate with removable eight-well columns was seeded for each donor. Each plate contained the following five treatment conditions: baseline growth-arrest medium (M199+l% PDS); growth-arrest medium containing hPDGF (5 ng/mL); or growth-arrest medium with hPDGF containing either 1, 10, or 25 fiM NPC-15669. There were two columns for each treatment medium, one for thymidine and the corresponding column for cell density measurement. The cells were grown and growth arrested as described above. On the third day after growth arrest, the cells were exposed to [ 3 H]thymidine at time 0 (baseline) or after 24 hours of exposure to the aforementioned conditions. The corresponding column that was to undergo colorimetric density determination received an equal volume of PBS. After 8 hours of thymidine exposure (1 jiCi/mL), columns containing thymidine were washed three times with ice-cold 10% trichloroacetic acid, the cells were lysed with 0.3N NaOH (200 /xL/well), the contents of each well were transferred to scintillation vials containing 5 mL scintillation fluid, and tritium was counted. The columns to undergo cell density determination were assayed as described above. All wells from a particular column were averaged, and the thymidine incorporation has been reported per 1,000 cells.
Effect of NPC-15669 on HAEC Proliferation
HAECs, passages 4-6, were obtained from liquid nitrogen storage. The cells were immediately thawed in a 37°C water bath and washed with EC growth medium (M199+10% FBS+ECGS + heparin). Five gelatinized 96-well tissue culture plates were seeded with 150 /xL of cell suspension (7,000 cells/well). After 24 hours in the initial EC growth medium, the cell density was determined in plate No. 1 (baseline), and the medium in each well of the remaining plates was changed to either fresh EC growth medium (control) or fresh EC growth medium containing one of four different concentrations of NPC-15669 (1, 10, 25, or 50 /iM). Each day another plate containing all of the conditions underwent cell density measurements. In each well of the remaining plates, the total amount of NPC-15669 per well was replenished with 20 /xL of the appropriate 8.5 x concentration of NPC-15669 in PBS. On day 3, however, half of the medium in all of the remaining plates was exchanged for fresh EC growth medium (control) or fresh EC growth medium containing the appropriate 2x concentration of NPC-15669. This experiment was repeated in cells from two different donors.
Effect of NPC-15669 on Cell Migration
We used a modification of the procedure described by Coomber and Gotlieb. 7 HAEC and HASMC cultures were grown to confluence on two-well, gelatinized, polystyrene tissue culture slides. At confluence a 1-mm wound was made across the middle of the slide by using a sterile cell scraper. After wounding, the wells were washed three times with warm PBS to remove all unattached cells. One well on each slide received the control growth medium while the other well received growth medium containing NPC-15669 at either 1,25, or 50 /xM. Each day the width of the wound was measured in each well. This study was repeated in triplicate. Figure 3a shows the dose-response effect of NPC-15669 on HASMCs. Day 0 values indicated no differences in the baseline cell density. However, after 3 days, wells treated with NPC-15669 at 25 fiM were 58.4% less dense than they were at day 0 and 53.6% less dense than control wells measured on the same day (/?>0.005). The density in the wells receiving 25 /xM NPC-15669 remained at this level throughout the rest of the experiment. There was no significant difference between cells treated with 1 and 10 fiM NPC-15669 and control cells on day 3. By day 6, however, there was a significant effect in the 10 ;u,M NPC-15669 wells. Cell counts increased 183.8% from days 3 to 6 in the control wells while the wells receiving 10 fiM NPC-15669 increased only 69.6%. Thus, on day 6 there were 40% fewer cells in wells receiving 10 /AM NPC-15669 compared with controls (p<0.005). Cell number in the wells receiving 1 )u,M NPC-15669 was not significantly different from control wells. Control wells and wells receiving 1.0 fiM NPC-15669 continued to show an increase in cell number from days 6 to 9, but 10 fiM NPC-15669 wells had a 32.2% decrease in cell number (p< 0.005) between days 6 and 9.
Results
Effect of NPC-15669 on HASMC Proliferation
Panels b and c from Figure 3 show experiments and results similar to those in Figure 3a except that the HASMCs were stimulated to proliferate with either 5 ng/mL hPDGF or 100 fM FGF. The growth factors alone (control) produced a consistent and significant increase in cell counts throughout the 4 days of exposure. The addition of NPC-15669 resulted in a concentration-dependent decrease in cell count. Figure 3b (hPDGF-stimulated cells) shows that the control wells increased 151.9% from days 0 to 2 while the wells receiving 10 /iM NPC-15669 had only an 80.5% increase. The wells receiving 50 fiM NPC-15669 showed a consistent decrease such that by the fourth day they were 79.4% less dense than day 4 controls (/><0.005). After 2 days the wells receiving 10 /xM NPC-15669 were 25.3% less dense than day 2 controls (p<0.005). The FGF-stimulated cells shown in Figure 3c demonstrated similar results. Control cells increased 159.7% from days 0 to 2 while 10 /xM NPC-15669-receiving cells increased only 77.7%. Control counts continued to increase from days 2 to 4, but the wells receiving 10 ^.M NPC-15669 showed a small decrease (52.2% lower than control,p<0.005). As with the hPDGF-stimulated cells, the wells receiving 50 /xM NPC-15669 showed a consistent decline in cell number such that by day 4, there was a 38.5% decrease from day 0 and an 83.7% decrease compared with day 4 controls (p<0.005).
NPC-15669 at lower concentrations (0.1 and 1.0 jtM) had no effect on cell density throughout the 9 days of exposure compared with control (data not shown). The data shown in Figure 3 are representative of data obtained from three different donors. NPC-15669 was effective in inhibiting all donor cells at concentrations between 10 and 25 Figure 4 illustrates the effect of various concentrations of NPC-15669 on [ Figure 5 shows the reversibility of the effect of treating FBS-stimulated HASMCs with 10 or 25 fiM NPC-15669 for 9 days (first group) and then replacing the NPC-15669-containing medium with fresh growth medium without NPC-15669. After 9 days' exposure, there were concentration-dependent decreases in cell count of 64.2% and 86.5%, respectively (p<0.005). Medium in the remaining plates was then changed to fresh growth medium without NPC-15669. After of fresh growth medium, cell counts in the control wells increased 40.8% while the wells that had previously been treated for 9 days with 10 pM NPC-15669 increased 135.6%. After 6 days in medium without NPC-15669, the recovery of the wells previously treated with 10 ^iM NPC-15669 was complete, i.e., not different from day 6 controls. Over the 6-day recovery period, the wells previously treated with 25 pM NPC-15669 showed no significant increase in cell count, i.e., no recovery. Figure 6 shows the effects of two other anti-inflammatory agents, aspirin and dexamethasone, added in high concentrations, on HASMCs and compares the decrease in cell number with that obtained with 10 /xM NPC-15669. The control wells demonstrated a progressive increase in cell number over the 9-day course. Cells exposed to NPC-15669 at 10 pM showed a slight but significant decrease in cell number compared with controls after 6 days, and after 9 days the NPC-15669 wells contained 76.1% fewer cells than day 9 controls (p<0.005). The aspirin and dexamethasone wells snowed progressive increases in cell number throughout the 9-day period that were comparable to controls; however, the rate of proliferation was slightly less, such that by day 9, there were 35.4% and 25.0% fewer cells in the aspirin and dexamethasone wells, respectively (p<0.005). Figure 7 shows that concentrations as high as 50 pM NPC-15669 had no significant effect on the proliferation of HAECs over a 4-day period of exposure. The cultures became confluent by day 4. Additionally, light microscopy revealed no obvious morphological differences between 50 pM NPC-15669-treated cells and controls (not shown). Figure 8 shows the relative, daily, and total migration of HAECs in the absence (control) and presence of various concentrations of NPC-15669. All culture wounds became confluent between days 3 and 4. There was no significant difference between control wells and any of the NPC-15669-treated wells. Similar results were obtained for HASMC migration.
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Discussion
This study demonstrates that NPC-15669, an Af-fluorenyl-9-methoxycarbonyl derivative of leucine, is capable of reducing or inhibiting the rate of proliferation of HASMCs in vitro in a dose-dependent and reversible manner. Furthermore, even at higher concentrations, it did not affect the proliferation of HAECs. There was variability in the sensitivity of HASMCs from various donors to the inhibitory effect, but a concentration of 25 /uM consistently produced marked inhibition of proliferation in HASMCs from all donors. There was also variability in the reversibility of the cells from different donors; the most sensitive cells showed little or no recovery at high concentrations of NPC-15669. Thymidine incorporation studies (reported as [ 3 H]thymidine incorporated in counts per minute per number of cells) support a decrease in proliferation as the primary cause for the decreasing cell density. Several growth factors are able to stimulate SMC proliferation; PDGF appears to be key, not only in stimulating proliferation but also potentially important in stimulating the migration of SMCs into the intima. 8 PDGF has been shown to have little or no effect on the proliferation of ECs compared with SMCs. 9 The selectivity of NPC-15669 for SMCs might be explained by this finding if its action were shown to be via PDGF or its receptor. For these reasons we studied the effects of NPC-15669 on proliferation and migration of hPDGF-stimulated cells and FGF-stimulated cells. We saw an equally potent inhibition of proliferation with either hPDGF-, FGF-, or FBS-stimulated cells. Also, in data not shown, NPC-15669 had no effect on hPDGF-stimulated HASMC migration.
With high concentrations or long exposure, NPC-15669 was able to reduce cell counts below baseline, indicating that under these conditions there was an increase in cell destruction. We conducted reversibility studies to help determine whether NPC-15669 was causing irreversible general toxicity. Our data suggest that if the agent is removed before the density of the culture drops below a critical point, recovery is prompt and complete ( Figure 5 ). This may be similar to the effects of seeding cultures too sparsely: if the culture is not seeded above a critical density, the cells will not proliferate. It is interesting to note that even at high concentrations (50 ^M), NPC-15669 did not inhibit either HAEC or HASMC migration. The stimulus for SMC migration and proliferation is transient, and reendothelialization of the site of injury may be important in terminating the stimulus. 1011 The reversibility and selectivity for SMCs versus ECs may allow NPC-15669 to prevent or attenuate SMC proliferation during a time of stimulation, and perhaps after reendothelialization, the agent could be stopped.
NPC-15669 has been shown to have anti-inflammatory activity in several different animals 12 -14 and has been found to be nontoxic at doses of 10 mg/kg body wt. 12 Recent data suggest that some of the anti-inflammatory activity of NPC-15669 may be through its ability to prevent the upregulation of the CD18 adhesion molecule in the neutrophil, 14 ' 15 thus preventing migration to the site of injury. This mechanism is unlike those of aspirin or dexamethasone. NPC-15669 is a leucine analogue with a relatively large side chain (Figure 1 ). Leucine-leucine interaction is important in the control of competence gene regulation because of its role in the leucine zipper that allows dimerization of JUN and FOS. 1617 It is possible that NPC-15669, because of its structural relation to leucine, interferes with this dimerization. We also tested both aspirin and dexamethasone at concentrations higher than those achieved in vivo. Even at these concentrations, these agents caused only a small decrease in cell number (Figure 6 ), and the effect was not dose dependent (data not shown).
Although in vitro cell culture provides a means for studying the direct effects of a particular agent on the cells, it has inherent limitations. The most significant shortcoming may be the absence of the inflammatory response that is present in vivo. Also, metabolism of the compound is bypassed in the in vitro model. Based on the data reported here, we propose NPC-15669 warrants further in vivo investigation as a potentially useful agent for the attenuation or prevention of post-PTCA restenosis.
